About
Dr. Yao-Chang Xu has more than 25 years of drug discovery and development experience in top pharmaceutical companies. Prior to founding Abbisko, Dr. Yao served as the General Manager of Hansoh Pharmaceutical Company. Serving as the first R&D head, he built a strong R&D team from blank and was responsible for overseeing all drug discovery programs. He successfully guided 10+ innovative programs from discovery to clinical development, spanning oncology, virology, CNS and other diseases. Prior to Hansoh, Dr. Yao served as Executive Director and Head of Chemistry at Novartis China, and Director of Chemistry at Eli Lilly in Indiana, USA. Dr. Yao obtained his Ph.D. from the University of Chicago and B.S. form Nanjing University. He is a member of the America Chemistry Society, Medicinal Chemistry, and Organic chemistry. He has published more than 50 international patents and numerous papers in peer-reviewed journals. He served as the reviewers many journals including J. Org. Chem., Org.
Position in the VCSift Database
- • 3 investors at Abbisko Therapeutics are tracked.
- • 3,360 investors hold the CEO role in VCSift. Yao-Chang Xu is one of them.
- • 1,074 investors are based in Shanghai, Shanghai, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Shanghai, China
Contact Information
Find more investors like Yao-Chang
Search Investors